Search

Your search keyword '"Keller, Norma"' showing total 131 results
Start Over Author "Keller, Norma" Search Limiters Full Text
131 results on '"Keller, Norma"'

1. Critical Care Cardiology Trials Network (CCCTN): a cohort profile.

Author

Metkus, Thomas, Baird-Zars, Vivian, Alfonso, Carlos, Alviar, Carlos, Barnett, Christopher, Barsness, Gregory, Berg, David, Bertic, Mia, Bohula, Erin, Burke, James, Burstein, Barry, Chaudhry, Sunit-Preet, Cooper, Howard, Daniels, Lori, Fordyce, Christopher, Ghafghazi, Shahab, Goldfarb, Michael, Katz, Jason, Keeley, Ellen, Keller, Norma, Kenigsberg, Benjamin, Kontos, Michael, Kwon, Younghoon, Lawler, Patrick, Leibner, Evan, Liu, Shuangbo, Menon, Venu, Miller, P, Newby, L, Papolos, Alexander, Pierce, Matthew, Prasad, Rajnish, Pisani, Barbara, Potter, Brian, Roswell, Robert, Sinha, Shashank, Shah, Kevin, Smith, Timothy, Snell, R, So, Derek, Solomon, Michael, Ternus, Bradley, Teuteberg, Jeffrey, van Diepen, Sean, Zakaria, Sammy, Morrow, David, and OBrien, Connor

Subjects
Cardiac ICU, Cohort, Critical care, Epidemiology, Humans, United States, Critical Illness, Coronary Care Units, Critical Care, Registries, Cardiology
Abstract

AIMS: The aims of the Critical Care Cardiology Trials Network (CCCTN) are to develop a registry to investigate the epidemiology of cardiac critical illness and to establish a multicentre research network to conduct randomised clinical trials (RCTs) in patients with cardiac critical illness. METHODS AND RESULTS: The CCCTN was founded in 2017 with 16 centres and has grown to a research network of over 40 academic and clinical centres in the United States and Canada. Each centre enters data for consecutive cardiac intensive care unit (CICU) admissions for at least 2 months of each calendar year. More than 20 000 unique CICU admissions are now included in the CCCTN Registry. To date, scientific observations from the CCCTN Registry include description of variations in care, the epidemiology and outcomes of all CICU patients, as well as subsets of patients with specific disease states, such as shock, heart failure, renal dysfunction, and respiratory failure. The CCCTN has also characterised utilization patterns, including use of mechanical circulatory support in response to changes in the heart transplantation allocation system, and the use and impact of multidisciplinary shock teams. Over years of multicentre collaboration, the CCCTN has established a robust research network to facilitate multicentre registry-based randomised trials in patients with cardiac critical illness. CONCLUSION: The CCCTN is a large, prospective registry dedicated to describing processes-of-care and expanding clinical knowledge in cardiac critical illness. The CCCTN will serve as an investigational platform from which to conduct randomised controlled trials in this important patient population.

Published
2022

2. Comparing Outcomes Between Advanced Practice Providers and Housestaff Teams in the Cardiac Intensive Care Unit

Author

Zhang, Robert S., Zhang, Peter, Bailey, Eric, Ho, Alvin, Rhee, Aaron, Xia, Yuhe, Schimmer, Hannah, Bernard, Samuel, Castillo, Patricio, Grossman, Kelsey, Dai, Matthew, Singh, Arushi, Padilla-Lopez, Mireia, Nunemacher, Kayla, Hall, Sylvie F., Rosenzweig, Barry, Katz, Jason N., Link, Nathan, Keller, Norma, Bangalore, Sripal, and Alviar, Carlos L.

Published
2024
Full Text
View/download PDF

3. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Author

Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, Kutcher, Matthew E, Laffan, Michael A, Lamontagne, Francois, and Le Gal, Grégoire

Subjects
Clinical Trials and Supportive Activities, Clinical Research, Comparative Effectiveness Research, Cardiovascular, Good Health and Well Being, Aged, Anticoagulants, COVID-19, Critical Illness, Female, Hemorrhage, Heparin, Hospital Mortality, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Respiration, Artificial, Thrombosis, Treatment Failure, COVID-19 Drug Treatment, REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.MethodsIn an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.ResultsThe trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio

Published
2021

4. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Author

Lawler, Patrick R, Goligher, Ewan C, Berger, Jeffrey S, Neal, Matthew D, McVerry, Bryan J, Nicolau, Jose C, Gong, Michelle N, Carrier, Marc, Rosenson, Robert S, Reynolds, Harmony R, Turgeon, Alexis F, Escobedo, Jorge, Huang, David T, Bradbury, Charlotte A, Houston, Brett L, Kornblith, Lucy Z, Kumar, Anand, Kahn, Susan R, Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S, Kim, Keri S, Gordon, Anthony C, Kirwan, Bridget-Anne, Brooks, Maria M, Higgins, Alisa M, Lewis, Roger J, Lorenzi, Elizabeth, Berry, Scott M, Berry, Lindsay R, Aday, Aaron W, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Costantini, Todd W, de Brouwer, Sophie, Derde, Lennie PG, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, García-Madrona, Sebastian, Girard, Timothy D, Godoy, Lucas C, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Hamburg, Naomi M, Haniffa, Rashan, Hanna, George, Hanna, Nicholas, Hegde, Sheila M, Hendrickson, Carolyn M, Hite, R Duncan, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Iyer, Vivek N, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei L, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, and Krishnan, Vidya

Subjects
Cardiovascular, Clinical Trials and Supportive Activities, Clinical Research, Hematology, Transplantation, Good Health and Well Being, Adult, Aged, Anticoagulants, COVID-19, Female, Hemorrhage, Heparin, Heparin, Low-Molecular-Weight, Hospital Mortality, Humans, Male, Middle Aged, Survival Analysis, Thrombosis, COVID-19 Drug Treatment, ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.MethodsIn this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.ResultsThe trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.ConclusionsIn noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).

Published
2021

5. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

Author

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, and Kutcher, Matthew E

Subjects
REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Humans, Thrombosis, Critical Illness, Hemorrhage, Heparin, Anticoagulants, Treatment Failure, Respiration, Artificial, Hospital Mortality, Logistic Models, Odds Ratio, Aged, Middle Aged, Female, Male, COVID-19, Clinical Research, Cardiovascular, Clinical Trials and Supportive Activities, Comparative Effectiveness Research, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.MethodsIn an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.ResultsThe trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio

Published
2021

6. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

Author

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, Patrick R, Goligher, Ewan C, Berger, Jeffrey S, Neal, Matthew D, McVerry, Bryan J, Nicolau, Jose C, Gong, Michelle N, Carrier, Marc, Rosenson, Robert S, Reynolds, Harmony R, Turgeon, Alexis F, Escobedo, Jorge, Huang, David T, Bradbury, Charlotte A, Houston, Brett L, Kornblith, Lucy Z, Kumar, Anand, Kahn, Susan R, Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S, Kim, Keri S, Gordon, Anthony C, Kirwan, Bridget-Anne, Brooks, Maria M, Higgins, Alisa M, Lewis, Roger J, Lorenzi, Elizabeth, Berry, Scott M, Berry, Lindsay R, Aday, Aaron W, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Costantini, Todd W, de Brouwer, Sophie, Derde, Lennie PG, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, García-Madrona, Sebastian, Girard, Timothy D, Godoy, Lucas C, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Hamburg, Naomi M, Haniffa, Rashan, Hanna, George, Hanna, Nicholas, Hegde, Sheila M, Hendrickson, Carolyn M, Hite, R Duncan, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Iyer, Vivek N, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei L, and King, Andrew J

Subjects
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Humans, Thrombosis, Hemorrhage, Heparin, Heparin, Low-Molecular-Weight, Anticoagulants, Hospital Mortality, Survival Analysis, Adult, Aged, Middle Aged, Female, Male, COVID-19, Hematology, Clinical Trials and Supportive Activities, Transplantation, Clinical Research, Cardiovascular, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundThrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.MethodsIn this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.ResultsThe trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.ConclusionsIn noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).

Published
2021

9. Abstract 17578: Improving Access to Care With a Structural Heart Disease Program in a Metropolitan Public Healthcare System

Author

Harari, Rafael, Bernard, Samuel, Shah, Binita, Nayar, Ambika, Small, Adam, Goldberg, Randal, Halpern, Dan, DiVita, Michael, Sutin, Kenneth, rostanski, sara, Lillemoe, Kaitlyn, Cruz, Jennifer, Elbaum, Lindsay, neuburger, peter, Hussain, Syed, Padilla Lopez, Mireia, Wan, Kah-Loon, Kroczynski, Nicolette, Jain, Sudheer, Alviar, Carlos L, Bangalore, Sripal, and Keller, Norma

Published
2023
Full Text
View/download PDF

12. Abstract 15659: Bupropion Overdose Requiring Veno-Arterial Extracorporeal Membrane Oxygenation

Author

Golob, Stephanie, Ting, Peter, Pires, Kyle, Soetanto, Vanessa, Pagano, Benjamin, Wan, Kah-Loon, Hall, Sylvie, Bianco, Lauren, Hawkins, Joseph, Schimmer, Hannah, Yunaev, Victoria, Howe, William, Landau, Jessica, Greco, Allison, Postelnicu, Radu, Harari, Rafael, Smith, Silas, Horowitz, James, Park, David, Keller, Norma, Bangalore, Sripal, Katz, Stuart, and Alviar, Carlos

Published
2023
Full Text
View/download PDF

17. A case report of sodium azide-induced myopericarditis.

Author

Tarabanis, Constantine, Banco, Darcy, Keller, Norma M, Bangalore, Sripal, and Alviar, Carlos L

Subjects
CARDIOGENIC shock, PERICARDITIS, CARDIOTOXICITY, SODIUM azide, VENTRICULAR ejection fraction, MENTAL depression, CELL physiology
Abstract

Background Sodium azide exposures are rare but can be lethal as the substance inhibits complex IV in the electron transport chain, blocking adenosine-triphosphate (ATP) synthesis. Sodium azide is mostly used as a propellant in vehicular airbags but is also used in laboratory, pharmacy, and industrial settings. No known antidote exists and its cardiotoxic effects are poorly described in the literature. Case summary We describe the case of a 31-year-old patient with major depressive disorder presenting with altered mental status after ingestion of an unknown amount of sodium azide. Although initially chest pain free, she developed pleuritic chest pain 48 h after ingestion. This was accompanied by new diffuse ST elevations on the electrocardiogram and serum troponin elevations concerning for myopericarditis. Treatment was pursued with a 14-day course of colchicine resulting in complete symptom resolution within 4 days of treatment initiation. The patient's transthoracic echocardiogram was only notable for a preserved left ventricular ejection fraction (LVEF). Discussion Cardiac toxicity after sodium azide ingestion usually occurs days after ingestion and has been previously described in the forms of heart failure with reduced ejection fraction complicated by cardiogenic shock. We describe the first case of sodium azide-induced myopericarditis with a preserved LVEF treated with colchicine. Colchicine is an established treatment for pericarditis, but its inhibition of endocytosis, an ATP-dependent cellular function, could be mechanistically relevant to this case. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Myocardial Injury in Adults Hospitalized With COVID-19

Author

Smilowitz, Nathaniel R., Jethani, Neil, Chen, Ji, Aphinyanaphongs, Yindalon, Zhang, Ruina, Dogra, Siddhant, Alviar, Carlos L., Keller, Norma, Razzouk, Louai, Quinones-Camacho, Adriana, Jung, Albert S., Fishman, Glenn I., Hochman, Judith S., and Berger, Jeffrey S.

Published
2020
Full Text
View/download PDF

22. C-33 | Clinical Outcomes After Percutaneous Mechanical Thrombectomy in Acute Pulmonary Embolism: A Real-World Single Center Experience

Author

Zhang, Robert S., primary, Yuriditsky, Eugene, additional, Alam, Usman, additional, Jaffe, Ian, additional, Grossman, Kelsey, additional, Singh, Arushi, additional, Greco, Allison A., additional, Postelnicu, Radu, additional, Mukherjee, Vikramjit, additional, Keller, Norma, additional, Alviar, Carlos L., additional, and Bangalore, Sripal, additional

Published
2023
Full Text
View/download PDF

23. Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial

Author

Stone, Gregg W., primary, Farkouh, Michael E., additional, Lala, Anuradha, additional, Tinuoye, Elizabeth, additional, Dressler, Ovidiu, additional, Moreno, Pedro R., additional, Palacios, Igor F., additional, Goodman, Shaun G., additional, Esper, Rodrigo B., additional, Abizaid, Alexandre, additional, Varade, Deepak, additional, Betancur, Juan F., additional, Ricalde, Alejandro, additional, Payro, Gerardo, additional, Castellano, José María, additional, Hung, Ivan FN, additional, Nadkarni, Girish N., additional, Giustino, Gennaro, additional, Godoy, Lucas C., additional, Feinman, Jason, additional, Camaj, Anton, additional, Bienstock, Solomon W., additional, Furtado, Remo H.M., additional, Granada, Carlos, additional, Bustamante, Jessica, additional, Peyra, Carlos, additional, Contreras, Johanna, additional, Owen, Ruth, additional, Bhatt, Deepak L., additional, Pocock, Stuart J., additional, Fuster, Valentin, additional, Lala, Anu, additional, Paul, Jonathan, additional, Pyo, Robert, additional, Baber, Usman, additional, Suh, Jason, additional, Saggar, Suraj, additional, Srivatsa, Sanjay, additional, Coylewright, Megan, additional, Chapparo, Sandra, additional, Melo, Jairo, additional, Keller, Norma, additional, Llanos, Alexander, additional, Chiu, Edwin, additional, Fahid, Ibrahim, additional, The, Angela, additional, Esper, Rodrigo Barbosa, additional, Ghetti Cabral, Ricardo Mauro, additional, Pompilio, Mauricio Antonio, additional, Cordeiro de Paula, Leonardo Jorge, additional, Airton de Arruda, Jose, additional, Filho, Roberto Kalil, additional, Faillace, Bruno, additional, Avancini Caramori, Paulo Ricardo, additional, da Silva Junior, Delcio Goncalves, additional, Neto, Eduardo Kowalski, additional, Nascif, Gibran Bhering, additional, Baccaro, Bruno Mendonca, additional, Cesar Cavalcanti, Rafael Rebelo, additional, Moraes Junior, Joao Batista, additional, Betancur, Juan Felipe, additional, Echeverri, Dario, additional, Beltran, Fernan Mendoza, additional, Renowistki Zabarain, Carlos Ramon, additional, Martinez Bula, Eduardo Antonio, additional, Fernandez, Angela María, additional, Melendez Flórez, Hector Julio, additional, Osorio, Wilder Castano, additional, Clavijo Moldón, Absalon Antonio, additional, Moreno, Antonio Figueredo, additional, Wong, Chun-Ka, additional, Varma, Madhumati, additional, Khanna, Aman, additional, Nikam, Prasad, additional, Bangi, Ashpak, additional, Gupta, Jugal Bihari, additional, Bhandari, Sudhir, additional, Sengupta, Shantanu, additional, Bhattacharya, Meenakshi, additional, Mehta, Nihar, additional, Aggarwal, Deepesh, additional, Uppe, Abhay, additional, Calcagno, Andrea, additional, Querini, Patrizia Rovere, additional, Narducci, Maria Lucia, additional, Guerrero, Jessica Paola, additional, Elizalde, Ivan, additional, Bello, Hector Herrera, additional, Cabrera, Otto Tavera, additional, Portano, Julieta Morales, additional, Riedel, Patricia Aubanel, additional, Llamas Esperon, Guillermo Antonio, additional, Guarena Casillas, Jorge Armando, additional, Azpiri, Jose Ramon, additional, Calvillo, Jorge Carrillo, additional, Lopez, Roberto Dominguez, additional, Barreto, Nancy Quezada, additional, Jaramillo, Ricardo, additional, Sokolski, Mateusz, additional, Fernandez, Paula Villares, additional, Moya Mateo, Eva Maria, additional, Varona Arche, Jose Felipe, additional, Mateo, Patricia Fanlo, additional, and Garcia Lomas, Mercedes Villareal, additional

Published
2023
Full Text
View/download PDF

25. Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry

Author

Berg, David D., Barnett, Christopher F., Kenigsberg, Benjamin B., Papolos, Alexander, Alviar, Carlos L., Baird-Zars, Vivian M., Barsness, Gregory W., Bohula, Erin A., Brennan, Joseph, Burke, James A., Carnicelli, Anthony P., Chaudhry, Sunit-Preet, Cremer, Paul C., Daniels, Lori B., DeFilippis, Andrew P., Gerber, Daniel A., Granger, Christopher B., Hollenberg, Steven, Horowitz, James M., Gladden, James D., Katz, Jason N., Keeley, Ellen C., Keller, Norma, Kontos, Michael C., Lawler, Patrick R., Menon, Venu, Metkus, Thomas S., Miller, P. Elliott, Nativi-Nicolau, Jose, Newby, L. Kristin, Park, Jeong-Gun, Phreaner, Nicholas, Roswell, Robert O., Schulman, Steven P., Sinha, Shashank S., Snell, R. Jeffrey, Solomon, Michael A., Teuteberg, Jeffrey J., Tymchak, Wayne, van Diepen, Sean, and Morrow, David A.

Published
2019
Full Text
View/download PDF

26. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units: Data From the Critical Care Cardiology Trials Network Registry

Author

Berg, David D., Bohula, Erin A., van Diepen, Sean, Katz, Jason N., Alviar, Carlos L., Baird-Zars, Vivian M., Barnett, Christopher F., Barsness, Gregory W., Burke, James A., Cremer, Paul C., Cruz, Jennifer, Daniels, Lori B., DeFilippis, Andrew P., Haleem, Affan, Hollenberg, Steven M., Horowitz, James M., Keller, Norma, Kontos, Michael C., Lawler, Patrick R., Menon, Venu, Metkus, Thomas S., Ng, Jason, Orgel, Ryan, Overgaard, Christopher B., Park, Jeong-Gun, Phreaner, Nicholas, Roswell, Robert O., Schulman, Steven P., Jeffrey Snell, R., Solomon, Michael A., Ternus, Bradley, Tymchak, Wayne, Vikram, Fnu, and Morrow, David A.

Published
2019
Full Text
View/download PDF

27. Toward Personalized DAPT: Is There an Inter-Manufacturer Difference in Generic Clopidogrel Response?

Author

Hall, Sylvie, Xia, Yuhe, Ahmed, Hamza, Iskhakov, Daniela, Feit, Frederick, Alviar, Carlos L., Berger, Jeffrey S., Keller, Norma, and Bangalore, Sripal

Subjects
Aspirin, Humans, Prospective Studies, Middle Aged, Social Group, Article, Aged, Clopidogrel, Retrospective Studies
Abstract

OBJECTIVE. To compare rates of clopidogrel response among patients receiving medication produced by 2 different manufacturers after acute coronary syndrome (ACS) and/or percutaneous coronary intervention. METHODS. This quality-improvement project included 515 adult patients receiving clopidogrel for ACS or ischemic heart disease and referred for coronary angiography/percutaneous coronary intervention. The project was divided into 2 phases: (1) retrospective collection of baseline data (April 2019-October 2020); and (2) two 12-week, prospective phases in which all clopidogrel in the hospital was restricted to a single manufacturer at a time (November 2020-May 2021). The primary outcome was clopidogrel response measured by platelet function testing, defined as adenosine diphosphate (ADP) response

Published
2022

35. ASSOCIATION BETWEEN POSITIVE END-EXPIRATORY PRESSURE, FILLING PRESSURES, AND MORTALITY IN MECHANICALLY VENTILATED PATIENTS WITH PRIMARILY LEFT OR RIGHT VENTRICULAR DYSFUNCTION

Author

Alviar, Carlos Leon, primary, Lui, Albert, additional, Jaramillo, Valentina, additional, Mesa, Juan Rico, additional, Pelaez, Alvaro Vargas, additional, Quien, Mary, additional, Aiad, Norman, additional, Alabdallah, Khaled, additional, Li, Boyangzi, additional, Masip, Josep, additional, Sionis, Alessandro, additional, Neto, Ary Serpa, additional, Keller, Norma, additional, Garber, Leonid, additional, Miller, P. Elliott, additional, Van Diepen, Sean, additional, and Smilowitz, Nathaniel Rosso, additional

Published
2020
Full Text
View/download PDF

36. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy: Results from the Bypass Angioplasty Revascularization Investigation (BARI)

Author

Berger, Peter B, Velianou, James L, Aslanidou Vlachos, Helen, Feit, Frederick, Jacobs, Alice K, Faxon, David P, Attubato, Michael, Keller, Norma, Stadius, Michael L, Weiner, Bonnie H, Williams, David O, and Detre, Katherine M

Published
2001
Full Text
View/download PDF

40. Sex and Race Are Associated With the Absence of Epicardial Coronary Artery Obstructive Disease at Angiography in Patients With Acute Coronary Syndromes

Author

Chokshi, Neel P., primary, Iqbal, Sohah N., additional, Berger, Rachel L., additional, Hochman, Judith S., additional, Feit, Frederick, additional, Slater, James N., additional, Pena‐Sing, Ivan, additional, Yatskar, Leonid, additional, Keller, Norma M., additional, Babaev, Anvar, additional, Attubato, Michael J., additional, and Reynolds, Harmony R., additional

Published
2010
Full Text
View/download PDF

42. Long-Term Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry

Author

Feit, Frederick, primary, Brooks, Maria Mori, additional, Sopko, George, additional, Keller, Norma M., additional, Rosen, Allan, additional, Krone, Ronald, additional, Berger, Peter B., additional, Shemin, Richard, additional, Attubato, Michael J., additional, Williams, David O., additional, Frye, Robert, additional, and Detre, Katherine M., additional

Published
2000
Full Text
View/download PDF

45. Endoventricular Remodeling of Left Ventricular Aneurysm

Author

Grossi, Eugene A., primary, Chinitz, Larry A., additional, Galloway, Aubrey C., additional, Delianides, Julie, additional, Schwartz, Daniel S., additional, McLoughlin, David E., additional, Keller, Norma, additional, Kronzon, Itzhak, additional, Spencer, Frank C., additional, and Colvin, Stephen B., additional

Published
1995
Full Text
View/download PDF

46. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy Results from the Bypass Angioplasty Revascularization Investigation (BARI)

Author

Berger, Peter B, Velianou, James L, Aslanidou Vlachos, Helen, Feit, Frederick, Jacobs, Alice K, Faxon, David P, Attubato, Michael, Keller, Norma, Stadius, Michael L, Weiner, Bonnie H, Williams, David O, and Detre, Katherine M

Subjects
surgical procedures, operative, cardiovascular diseases
Abstract

OBJECTIVESWe sought to compare survival after coronary artery bypass graft (CABG) and percutaneous transluminal coronary angioplasty (PTCA) in high-risk anatomic subsets.BACKGROUNDCompared with medical therapy, CABG decreases mortality in patients with three-vessel disease and two-vessel disease involving the proximal left anterior descending artery (LAD), particularly if left ventricular (LV) dysfunction is present. How survival after PTCA and CABG compares in these high-risk anatomic subsets is unknown.METHODSIn the Bypass Angioplasty Revascularization Investigation (BARI), 1,829 patients with multivessel disease were randomized to an initial strategy of PTCA or CABG between 1988 and 1991. Stents and IIb/IIIa inhibitors were not utilized. Since patients in BARI with diabetes mellitus had greater survival with CABG, separate analyses of patients without diabetes were performed.RESULTSSeven-year survival among patients with three-vessel disease undergoing PTCA and CABG (n = 754) was 79% versus 84% (p = 0.06), respectively, and 85% versus 87% (p = 0.36) when only non-diabetics (n = 592) were analyzed. In patients with three-vessel disease and reduced LV function (ejection fraction

Full Text
View/download PDF

49. Abstract 151

Author

Keller, Norma and McWhir, Gregory J

Published
2012

50. Evaluating the hemodynamic impact of saddle versus non-saddle pulmonary embolism: insights from a thrombectomy cohort.

Author

Zhang RS, Yuriditsky E, Bailey E, Elbaum L, Greco AA, Postelnicu R, Mukherjee V, Keller N, Alviar CL, Horowitz JM, and Bangalore S

Abstract

Objectives: The aim of this study was to compare the hemodynamic impact and clinical outcomes of saddle vs non-saddle pulmonary embolism (PE)., Methods: This was a retrospective analysis of clinical characteristics and outcomes among patients with saddle and non-saddle PE within a cohort referred for catheter-based thrombectomy (CBT) with invasive hemodynamic assessments. Patients who underwent CBT between August 2020 and January 2024 were included. The primary outcome was the proportion of patients with a low cardiac index (CI < 2.2 L/min/m²). Secondary outcomes included 30-day mortality, intensive care unit (ICU) length of stay (LOS), and hospital LOS., Results: A total of 107 patients (84 intermediate risk, 23 high-risk; mean age 58 years, 47.6% female) were included in the study, with 44 patients having saddle PE and 63 having non-saddle PE. There were no significant differences in baseline demographics and clinical characteristics between saddle and non-saddle PE, including rates of high-risk PE (25% vs 16%, P = .24), rates of RV dysfunction, pulmonary artery systolic pressure (55 vs 53 mm Hg, P = .74), mean pulmonary artery pressure (34 mm Hg vs 33 mm Hg), low cardiac index (56% vs 51%, P = .64), rates of normotensive shock (27% vs 20%, P = .44), or Composite Pulmonary Embolism Shock scores (4.5 vs 4.7, P = .25). Additionally, 30-day mortality (6% vs 5%, P = .69), ICU LOS, and hospital LOS were similar between the groups., Conclusions: Among patients undergoing CBT, there were no significant differences in invasive hemodynamic parameters or clinical outcomes between those with saddle and non-saddle PE.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results